Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment

MT Newswires Live

05/30

Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.

The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.

The company anticipates receiving the milestone payment from Fuso within 30 days.

Shares rose nearly 2% in morning trade Friday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539905282"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539905282\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539905282?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-30 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539905282","market":"us","top_or_hot":-1,"title":"Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.</p><p>The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.</p><p>The company anticipates receiving the milestone payment from Fuso within 30 days.</p><p>Shares rose nearly 2% in morning trade Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Confirms First Japan Clinical Trial Site Open for Recruitment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-30 09:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.</p><p>The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.</p><p>The company anticipates receiving the milestone payment from Fuso within 30 days.</p><p>Shares rose nearly 2% in morning trade Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2539905282","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539905282","pubTimestamp":1748566849,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix  confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.The company anticipates receiving the milestone payment from Fuso within 30 days.Shares rose nearly 2% in morning trade Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7501":"新冠治疗股","BK7067":"生物科技","DXB.AU":"DIMERIX LTD"},"translate_title":"Dimerix确认首个日本临床试验中心开放招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB.AU":0.9},"content_text":"Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.The company anticipates receiving the milestone payment from Fuso within 30 days.Shares rose nearly 2% in morning trade Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}